ArticleFrontiers in nutrition2025
Comprehensive safety evaluation of
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and safety of ashwagandha root extract in children and adolescents with mild attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled trial.Journal of medicine and life · 2026Trial
- The interplay of Ashwagandha with hormonal dynamics and gut microbiota in women with breast cancer: a tri-axial perspective.Journal of natural medicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study evaluates the safety profiles of Methods: We employed natural language processing (NLP) to systematically review existing literature and utilized quantitative structure-activity relationship (QSAR) models to predict liver and reproductive toxicity at the molecular level. Special attention was given to withanolides, the bioactive compounds in Ashwagandha, due to conflicting safety information. Additionally, we reviewed case studies reporting liver toxicity, noting that many involved supplements containing both leaves and roots, complicating the identification of the toxicity source. Results: Our analysis indicated that Ashwagandha root exhibits a superior safety profile compared to non-root parts, particularly concerning liver and reproductive toxicity. When compared to a broad set of other herbal supplements, Ashwagandha root was found to have a better safety profile than most, making it a first-choice ingredient for safe and effective use in supplements. While non-root parts of Ashwagandha showed higher toxicity potential than the root, their safety profile was still comparable to other edible plants and herbal supplements. Conclusion: This study suggests that the root of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.